Consolidated 1H25 revenue landed at €905m discounting a 15.6% comparable decline. This compares to our revenue of €1016mE and company compiled CSS of €984m. Adjusted EBIT landed at €21m well below our (€75m) and CSS (€61m) estimates. Backlog bottoming out at € 1451m or flat (0.3%) at comparable basis. Ongoing restructuring should save €80-100m annually upon completion and (at the mid point) full year guidance calls for € 189m EBIT25. 2Q EBIT shows first signs of savings kicking in. Leverage well...
Alfen: Preview - muddling through? Belgian telcos: Competition Authority investigation on Proximus/Orange Belgium MoU. Brunel International: 2Q25 below, 3Q25 outlook cut, cost savings protect FY25 estimates. Euronext: Another record set of results. Fugro: Sharper V-shape? GBL: Weak NAV performance, as expected. KBC Ancora: Cooperative CERA increasing its stake to 51.24%, using excess cash. UCB: Renewed US threats to cut drug prices. Umicore: 1H25 and guide broadly in-line, new S...
X-Fab presented a solid set of 2Q25 results and expect this positive trend to continue in 2H25. We saw an above-average order intake for X-Fab's microsystems business. With the completion of its CapEx program, X-Fab claims it is ideally positioned to grow profitably together with its customers (mainly Melexis). Sufficient capacity is now available for its most popular technologies, suited to address the megatrends of our time, such as the electrification of everything. This will generate high de...
Sequana announced the publication of a case report of a patient in the POSEIDON study that underwent a successful robotic hernia repair following control of their ascites with the alfapump. Looking ahead, the US commercial launch remains on track for this quarter. Should the company demonstrate initial commercial traction during the soft launch phase, this could trigger additional investor interest to fund the company into the broader launch, which is expected in 2Q26. We reiterate our € 5 TP an...
1H25 adj. EBITDA increased by 10% to 433m and Umicore reiterated the (recently upgraded) FY25 adj EBITDA guidance of 790-840m (+7% y/y at midpoint), reflecting oa the progress with efficiency improvement measures and advantageous metal prices. Umicore is a combination of different tales, with the foundation businesses (Catalysis, Recycling, Specialty Materials) mainly run for their cash generation potential whilst Battery Materials remains a potential growth driver, although Umicore does not int...
Euronext publishes Q2 2025 results Euronext publishes Q2 2025 results Euronext’s diversified business drives all-time record results, supported by organic growth, favourable market conditions and disciplined capital allocation. Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 31 July 2025 – Euronext, the leading European capital market infrastructure, today publishes its results for the second quarter of 2025. Q2 2025 revenue and income was up +12.8% to €465.8 million: Non-volume-related revenue and income represented 58% of total revenue and income and covered 161% of unde...
1H25 net revs were flat (-0.1% organically) at €1937m (vs. our €1960m and css of €1957m). Operating EBITA landed at €215m below our €222m but inline with css of €215m. Sequentially the backlog fell slightly over 2Q to €976m (still +2.6% organically ytd), with 2Q book-to-bill ratio of 1.0x (vs. 1.1x in 1Q25). Overall results were in line but both revenue and order intake dynamics at Resilience are somewhat subdue, in spite of the solid margin performance of the GBA. Mobility remains on track for ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.